DefEYE announced an investment from ExSight Ventures for its decellularized placental-based tissue platform designed for ocular surface disease and ocular surgical management. The company is developing a portfolio of decellularized biologic solutions intended to optimize treatment and management across conditions including ocular surface diseases and pterygium surgery, according to the release. 

The funding will support commercialization through continued growth and expansion, the companies said. ExSight characterized DefEYE’s approach as an innovative entry in ocular biologics. 

“ExSight’s investment defies our initial skepticism of the technology and the market,” said Firas Rahhal, cofounder at ExSight Ventures, noting feedback that pointed to “better clinical outcomes, improved patient experience, and consequently, growing adoption.” 

“ExSight Ventures’ deep knowledge and long-standing commitment to advancing innovation in the ophthalmic space make them an ideal strategic partner for DefEYE,” said Rob Sambursky, MD, chief executive officer of DefEYE. He added that the investment supports the company’s vision to “accelerate the adoption of regenerative therapies that elevate the clinical management of both ocular surface disease and ocular surgery.” 

The companies did not disclose additional terms.